Baxter International (BAX)
(Delayed Data from NYSE)
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Zacks News
Varian Medical (VAR) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Strong overseas presence and product launches are likely to aid Varian Medical's (VAR) fiscal first-quarter results.
Stock Market News For Jan 8, 2019
by Zacks Equity Research
Wall Street rallied for the second consecutive day on Monday after resumption of trade related negotiations between the United States and China
Baxter's PD Solution to Treat Patients, Prospects Bright
by Zacks Equity Research
Baxter's (BAX) kidney care portfolio likely to favor the company as kidney care demand shoots up in the United States.
Can Baxter (BAX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III
by Zacks Equity Research
Mallinckrodt (MNK) and partner NPXe Limited enrol the first patient in the phase III study on xenon gas for inhalation (XENEX) for Post Cardiac Arrest Syndrome (PCAS).
Stock Market News For Dec 19, 2018
by Zacks Equity Research
U.S. stocks closed mostly higher on Tuesday after a volatile session, reversing stiff decline in previous two trading days
Baxter Stock up on Launch of Disposable Curved Applicator
by Zacks Equity Research
Baxter's (BAX) wide array of surgical products see lucrative market prospects.
Here's Why You Should Hold Baxter International (BAX) Now
by Zacks Equity Research
Baxter's (BAX) recent string of developments boost the stock while segmental softness is a concern.
Baxter & EFCNI Collaborate to Improve Care for Preterm Born
by Zacks Equity Research
Baxter's (BAX) latest move is likely to increase the use of Baxter's Numeta G13E triple-chamber PN product.
Why Is Baxter (BAX) Up 7.9% Since Last Earnings Report?
by Zacks Equity Research
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Baxter (BAX) Launches Peri-Strips & Tisseel Prima, Shares Up
by Zacks Equity Research
Baxter's (BAX) diversified surgical portfolio lends it a competitive edge in the MedTech space.
Company News For Nov 1, 2018
by Zacks Equity Research
Companies In The News Are: TMUS,S,K,BAX
Top Analyst Reports for Amazon, Facebook, Mastercard & Merck
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Amazon (AMZN), Facebook (FB), Mastercard (MA) and Merck (MRK).
Baxter (BAX) Earnings Beat, Revenues Lag Estimates in Q3
by Zacks Equity Research
Baxter (BAX) gains from Renal Care and Advanced Surgery units in Q3; APAC sales soft.
Baxter International (BAX) Tops Q3 Earnings Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 8.11% and -0.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Q3 Earnings on Oct 31: BAX, MASI & More
by Zacks Equity Research
Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
We are encouraged by Zimmer Biomet's (ZBH) consistent effort in product renovation through research and development.
Cerner's (CERN) Q3 Earnings Match Estimates, Bookings Up Y/Y
by Zacks Equity Research
Cerner (CERN) gains from strong segmental revenues in the third quarter. Guidance for 2018 is impressive.
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
Omnicell's (OMCL) third-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.
ResMed (RMD) Q1 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) sees solid contributions from domestic and international businesses in Q1.
Merit Medical (MMSI) Tops Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) gains from solid segmental performance in Q3. Also, the company reiterated its guidance for 2018.
Stryker (SYK) Beats Q3 Earnings, Misses Sales Estimates
by Zacks Equity Research
Stryker's (SYK) Q3 results benefit from solid segmental performance. Also, the company sustained strength in International sales.
Will Advance Medical Buyout Aid Teladoc (TDOC) Q3 Earnings?
by Zacks Equity Research
Teladoc (TDOC) is expected to chip in with a solid top-line contribution from its acquisition of Advance Medical in Q3.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q3 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) efforts to enhance its commercial capabilities in the United States to maintain a recurring revenue rise at CAG Diagnostics are encouraging.
Will Product Revenues Drive Masimo's (MASI) Q3 Earnings?
by Zacks Equity Research
Masimo's (MASI) Product revenues likely to drive Q3; guidance for 2018 raised.